Last deal

Amount

Series A

Stage

15.09.2012

Date

1

all rounds

date founded

Financing round

General

About Company
cCAM Biotherapeutics develops immunotherapies for cancer.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2009

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

The pre-clinical stage company's lead agent, CM-10, is an immunomodulatory antibody that targets CEACAM1, a protein used by cancer cells to suppress the immune system, and abrogates its effect. This leads to a cancer-specific immune response in patients. In addition to CM-10, cCAM Biotherapeutics also develops monoclonal antibodies for cancer treatment therapies, focusing on novel immunotherapies for different cancer indications.
Contacts
Similar Companies
1000
Pionyr Immunotherapeutics

Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is developing cancer immunotherapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

South San Francisco, CA, USA

total rounds

4

total raised

$352M
Metaclipse Therapeutics

Metaclipse Therapeutics

Metaclipse Therapeutics is a biotech company developing personalized cancer immunotherapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Atlanta, GA, USA

total rounds

6

total raised

$2.55M
ITeos Therapeutics

ITeos Therapeutics

ITeos Therapeutics is a biotechnology company specializing in tumor immunology and cancer immunotherapy.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Cambridge, MA, USA

total rounds

9

total raised

$369.74M
Selecxine

Selecxine

Selecxine is a biotech company that develops immunotherapeutics for cancer patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Songpa-dong, Songpa-gu, Seoul, South Korea

total rounds

3

total raised

$27.29M
M&A Details
1

Acquired by

Merck Sharp & Dohme Sweden AB

announced date

28.07.2015

price

$95M

Financials

Funding Rounds
1
1

Number of Funding Rounds

Their latest funding was raised on 15.09.2012. Their latest investor Pontifax. Their latest round Series A

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Arkin Holdings

Arkin Holdings

Arkin Holdings empowers breakthrough healthcare companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

Herzliya, Israel

count Of Investments

22

count Of Exists

1
Co-Investors
Investors
3
1

Number of lead investors

3

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series A
No
Series A
Yes
Series A
Pontifax

Pontifax

Pontifax is a healthcare-dedicated venture capital firm that finances pharmaceutical and life sciences companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Herzliya, Israel

count Of Investments

97

count Of Exists

9
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

561

count Of Exists

82
Arkin Holdings

Arkin Holdings

Arkin Holdings empowers breakthrough healthcare companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

Herzliya, Israel

count Of Investments

22

count Of Exists

1

People

Employee Profiles
1
Gal Markel

Gal Markel

Founder and Chief Scientific Officer

Activity

Recent News
0